Activation of p53 by small molecule MDM2 inhibitors can induce cell cycle arrest or death in p53 wildtype cancer cells. However, cancer cells exposed to hypoxia can develop resistance to other small molecules, such as chemotherapies, that activate p53. Here, we evaluated whether hypoxia could render cancer cells insensitive to two MDM2 inhibitors with different potencies, nutlin-3a and navtemadlin. Inhibitor efficacy and potency were evaluated under short-term hypoxic conditions in human and mouse cancer cells expressing different p53 genotypes (wild-type, mutant, or null). Treatment of wild-type p53 cancer cells with MDM2 inhibitors reduced cell growth by > 75% in hypoxia through activation of the p53-p21 signaling pathway; no inhibitor-induced growth reduction was observed in hypoxic mutant or null p53 cells except at very high concentrations. The concentration of inhibitors needed to induce the maximal p53 response was not significantly different in hypoxia compared to normoxia. However, inhibitor efficacy varied by species and by cell line, with stronger effects at lower concentrations observed in human cell lines than in mouse cell lines grown as 2D and 3D cultures. Together, these results indicate that MDM2 inhibitors retain efficacy in hypoxia, suggesting they could be useful for targeting acutely hypoxic cancer cells.

Department of Medical Cell Biology Uppsala University 751 23 Uppsala Sweden

Department of Medicine Solna Center for Molecular Medicine Karolinska University Hospital and Karolinska Institutet 171 77 Stockholm Sweden

Department of Microbiology Tumor and Cell Biology Karolinska Institutet 171 77 Stockholm Sweden

Moderna Therapeutics 200 Technology Square Cambridge MA 02139 USA

RECAMO Masaryk Memorial Cancer Institute 656 53 Brno Czech Republic

Zobrazit více v PubMed

Boutelle AM, Attardi LD. p53 and tumor suppression: It takes a network. Trends Cell Biol. 2021;31:298–310. doi: 10.1016/j.tcb.2020.12.011. PubMed DOI PMC

Bouaoun L, et al. TP53 variations in human cancers: New lessons from the IARC TP53 database and genomics data. Hum. Mutat. 2016;37:865–876. doi: 10.1002/humu.23035. PubMed DOI

Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP. Awakening guardian angels: Drugging the P53 pathway. Nat. Rev. Cancer. 2009;9:862–873. doi: 10.1038/nrc2763. PubMed DOI

Burgess A, et al. Clinical overview of MDM2/X-targeted therapies. Front. Oncol. 2016;6:1–7. doi: 10.3389/fonc.2016.00007. PubMed DOI PMC

Spiegelberg D, et al. The MDM2/MDMX-p53 antagonist PM2 radiosensitizes wild-type p53 tumors. Cancer Res. 2018;78:5084–5093. doi: 10.1158/0008-5472.CAN-18-0440. PubMed DOI

Vassilev L, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science (80-) 2004;303:844–849. doi: 10.1126/science.1092472. PubMed DOI

Werner LR, et al. Small molecule inhibition of MDM2-p53 interaction augments radiation response in human tumors. Mol. Cancer Ther. 2015;14:1994–2003. doi: 10.1158/1535-7163.MCT-14-1056-T. PubMed DOI

Lakoma A, et al. The MDM2 small-molecule inhibitor RG7388 leads to potent tumor inhibition in p53 wild-type neuroblastoma. Cell Death Discov. 2015;1:1–9. doi: 10.1038/cddiscovery.2015.26. PubMed DOI PMC

Her NG, et al. Potent effect of the MDM2 inhibitor AMG232 on suppression of glioblastoma stem cells. Cell Death Dis. 2018;9:1–12. doi: 10.1038/s41419-018-0825-1. PubMed DOI PMC

Barbieri E, et al. MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death. Mol. Cancer Ther. 2006;5:2358–2365. doi: 10.1158/1535-7163.MCT-06-0305. PubMed DOI

Sun D, et al. Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2—p53 inhibitor in clinical development. J. Med. Chem. 2014;57:1454–1472. doi: 10.1021/jm401753e. PubMed DOI

Nguyen MN, et al. Discovering putative protein targets of small molecules: A study of the p53 activator nutlin. J. Chem. Inf. Model. 2019;59:1529–1546. doi: 10.1021/acs.jcim.8b00762. PubMed DOI

Supiot S, Hill RP, Bristow RG. Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53. Mol. Cancer Ther. 2008;7:993–999. doi: 10.1158/1535-7163.MCT-07-0442. PubMed DOI

Valentine JM, Kumar S, Moumen A. A p53-independent role for the MDM2 antagonist Nutlin-3 in DNA damage response initiation. BMC Cancer. 2011;11:1–11. doi: 10.1186/1471-2407-11-79. PubMed DOI PMC

Haronikova L, et al. Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: Can we overcome them? Cell. Mol. Biol. Lett. 2021;26:1–33. doi: 10.1186/s11658-021-00293-6. PubMed DOI PMC

Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat. Rev. Cancer. 2004;4:437–447. doi: 10.1038/nrc1367. PubMed DOI

Cosse JP, Ronvaux M, Ninane N, Raes MJ, Michiels C. Hypoxia-induced decrease in p53 protein level and increase in c-jun DNA binding activity results in cancer cell resistance to etoposide. Neoplasia. 2009;11:976–986. doi: 10.1593/neo.09632. PubMed DOI PMC

Strese S, Fryknäs M, Larsson R, Gullbo J. Effects of hypoxia on human cancer cell line chemosensitivity. BMC Cancer. 2013;13:1–11. doi: 10.1186/1471-2407-13-331. PubMed DOI PMC

Harris AL. Hypoxia—A key regulatory factor in tumour growth. Nat. Rev. Cancer. 2002;2:38–47. doi: 10.1038/nrc704. PubMed DOI

Nijhuis A, et al. Remodelling of microRNAs in colorectal cancer by hypoxia alters metabolism profiles and 5-fluorouracil resistance. Hum. Mol. Genet. 2017;26:1552–1564. doi: 10.1093/hmg/ddx059. PubMed DOI PMC

Jiang Z, et al. Ribosome profiling reveals translational regulation of mammalian cells in response to hypoxic stress. BMC Genom. 2017;18:1–12. doi: 10.1186/s12864-017-3996-8. PubMed DOI PMC

Marcel V, Catez F, Diaz JJ. P53, a translational regulator: Contribution to its tumour-suppressor activity. Oncogene. 2015;34:5513–5523. doi: 10.1038/onc.2015.25. PubMed DOI

Graeber TG, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in Solid Tumours. Nature. 1996;379:88–91. doi: 10.1038/379088a0. PubMed DOI

Ortmann B, Druker J, Rocha S. Cell cycle progression in response to oxygen levels. Cell. Mol. Life Sci. 2014;71:3569–3582. doi: 10.1007/s00018-014-1645-9. PubMed DOI PMC

Bhandari V, et al. Molecular landmarks of tumor hypoxia across cancer types. Nat. Genet. 2019;51:308–318. doi: 10.1038/s41588-018-0318-2. PubMed DOI

Yang J, et al. Small-molecule activation of p53 blocks hypoxia-inducible factor 1 and vascular endothelial growth factor expression in vivo and leads to tumor cell apoptosis in normoxia and hypoxia. Mol. Cell. Biol. 2009;29:2243–2253. doi: 10.1128/MCB.00959-08. PubMed DOI PMC

Weilbacher A, Gutekunst M, Oren M, Aulitzky WE, Van Der Kuip H. RITA can induce cell death in p53-defective cells independently of p53 function via activation of JNK/SAPK and p38. Cell Death Dis. 2014;5:e1318–e1411. doi: 10.1038/cddis.2014.284. PubMed DOI PMC

De Lange J, et al. Synergistic growth inhibition based on small-molecule p53 activation as treatment for intraocular melanoma. Oncogene. 2012;31:1105–1116. doi: 10.1038/onc.2011.309. PubMed DOI

Ingelshed K, et al. The MDM2 inhibitor navtemadlin arrests mouse melanoma growth in vivo and potentiates radiotherapy. Cancer Res. Commun. 2022;2:1075–1088. doi: 10.1158/2767-9764.CRC-22-0053. PubMed DOI PMC

Brimacombe K, et al. A dual-fluorescence high-throughput cell line system for probing multidrug resistance. Assay Drug Dev. Technol. 2009;7:233–249. doi: 10.1089/adt.2008.165. PubMed DOI PMC

Canon J, et al. The MDM2 inhibitor AMG 232 demonstrates robust antitumor efficacy and potentiates the activity of p53-inducing cytotoxic agents. Mol. Cancer Ther. 2015;14:649–658. doi: 10.1158/1535-7163.MCT-14-0710. PubMed DOI

Vojtěšek B, Bártek J, Midgley CA, Lane DP. An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J. Immunol. Methods. 1992;151:237–244. doi: 10.1016/0022-1759(92)90122-A. PubMed DOI

Howes AL, Richardson RD, Finlay D, Vuori K. 3-Dimensional culture systems for anti-cancer compound profiling and high-throughput screening reveal increases in EGFR inhibitor-mediated cytotoxicity compared to monolayer culture systems. PLoS ONE. 2014;9:e108283. doi: 10.1371/journal.pone.0108283. PubMed DOI PMC

Imamura Y, et al. Comparison of 2D- and 3D-culture models as drug-testing platforms in breast cancer. Oncol. Rep. 2015;33:1837–1843. doi: 10.3892/or.2015.3767. PubMed DOI

Muguruma M, Teraoka S, Miyahara K, Ueda A, Asaoka M. Differences in drug sensitivity between two-dimensional and three-dimensional culture systems in triple-negative breast cancer cell lines. Biochem. Biophys. Res. Commun. 2020;533:268–274. doi: 10.1016/j.bbrc.2020.08.075. PubMed DOI

Chen W, et al. High-throughput image analysis of tumor spheroids: A user-friendly software application to measure the size of spheroids automatically and accurately. J. Vis. Exp. 2014;89:51639. PubMed PMC

Grimes DR, et al. The role of oxygen in avascular tumor growth. PLoS ONE. 2016;11:1–19. doi: 10.1371/journal.pone.0153692. PubMed DOI PMC

Hirschhaeuser F, et al. Multicellular tumor spheroids: An underestimated tool is catching up again. J. Biotechnol. 2010;148:3–15. doi: 10.1016/j.jbiotec.2010.01.012. PubMed DOI

Härmä V, et al. A comprehensive panel of three-dimensional models for studies of prostate cancer growth, invasion and drug responses. PLoS ONE. 2010;5:e10431. doi: 10.1371/journal.pone.0010431. PubMed DOI PMC

Luca AC, et al. Impact of the 3D microenvironment on phenotype, gene expression, and EGFR inhibition of colorectal cancer cell lines. PLoS ONE. 2013;8:e59689. doi: 10.1371/journal.pone.0059689. PubMed DOI PMC

Russell S, Wojtkowiak J, Neilson A, Gillies RJ. Metabolic profiling of healthy and cancerous tissues in 2D and 3D. Sci. Rep. 2017;7:1–11. doi: 10.1038/s41598-017-15325-5. PubMed DOI PMC

Riedl A, et al. Comparison of cancer cells in 2D vs 3D culture reveals differences in AKT-mTOR-S6K signaling and drug responses. J. Cell Sci. 2017;130:203–218. PubMed

Riffle S, Pandey RN, Albert M, Hegde RS. Linking hypoxia, DNA damage and proliferation in multicellular tumor spheroids. BMC Cancer. 2017;17:1–12. doi: 10.1186/s12885-017-3319-0. PubMed DOI PMC

Grimes DR, Kelly C, Bloch K, Partridge M. A method for estimating the oxygen consumption rate in multicellular tumour spheroids. J. R. Soc. Interface. 2014;11:20131124. doi: 10.1098/rsif.2013.1124. PubMed DOI PMC

Gluck WL, et al. Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma. Investig. New Drugs. 2020;38:831–843. doi: 10.1007/s10637-019-00840-1. PubMed DOI PMC

Honda R, Yasuda H. Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J. 1999;18:22–27. doi: 10.1093/emboj/18.1.22. PubMed DOI PMC

Pomerantz J, et al. The Ink4a tumor suppressor gene product, p19(Arf), interacts with MDM2 and neutralizes MDM2’s inhibition of p53. Cell. 1998;92:713–723. doi: 10.1016/S0092-8674(00)81400-2. PubMed DOI

Merkel CA, et al. Activation of endogenous p53 by combined p19Arf gene transfer and nutlin-3 drug treatment modalities in the murine cell lines B16 and C6. BMC Cancer. 2010;10:1–14. doi: 10.1186/1471-2407-10-316. PubMed DOI PMC

Box AH, Demetrick DJ. Cell cycle kinase inhibitor expression and hypoxia-induced cell cycle arrest in human cancer cell lines. Carcinogenesis. 2004;25:2325–2335. doi: 10.1093/carcin/bgh274. PubMed DOI

Yoshiba S, et al. Hypoxia induces resistance to 5-fluorouracil in oral cancer cells via G1 phase cell cycle arrest. Oral Oncol. 2009;45:109–115. doi: 10.1016/j.oraloncology.2008.04.002. PubMed DOI

Fatyol K, Szalay AA. The p14ARF tumor suppressor protein facilitates nucleolar sequestration of hypoxia-inducible factor-1α (HIF-1α) and inhibits HIF-1-mediated transcription. J. Biol. Chem. 2001;276:28421–28429. doi: 10.1074/jbc.M102847200. PubMed DOI

LeBlanc L, et al. Β-catenin links cell seeding density to global gene expression during mouse embryonic stem cell differentiation. iScience. 2022;25:103541. doi: 10.1016/j.isci.2021.103541. PubMed DOI PMC

Xue Y, et al. Bortezomib stabilizes and activates p53 in proliferative compartments of both normal and tumor tissues in vivo. Cancer Res. 2019;79:3595–3607. doi: 10.1158/0008-5472.CAN-18-3744. PubMed DOI

Harnessing p53 for targeted cancer therapy: new advances and future directions